Q1 Earnings Estimate for VRDN Issued By Wedbush

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at Wedbush issued their Q1 2026 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($1.17) for the quarter. Wedbush currently has a “Outperform” rating and a $42.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2028 earnings at $9.52 EPS.

A number of other analysts also recently commented on VRDN. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a report on Thursday, September 19th. HC Wainwright upped their price objective on Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday. Finally, The Goldman Sachs Group lifted their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

Viridian Therapeutics Stock Up 0.6 %

NASDAQ VRDN traded up $0.14 on Thursday, reaching $22.62. The company had a trading volume of 45,552 shares, compared to its average volume of 1,110,581. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average is $22.35 and its 200 day moving average is $16.89. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The stock has a market capitalization of $1.45 billion, a P/E ratio of -5.22 and a beta of 1.10.

Insider Activity

In other news, CEO Stephen F. Mahoney bought 21,400 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. The purchase was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Stephen F. Mahoney acquired 21,400 shares of Viridian Therapeutics stock in a transaction on Friday, September 27th. The shares were acquired at an average cost of $23.33 per share, with a total value of $499,262.00. Following the transaction, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Thomas W. Beetham bought 5,000 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $23.41 per share, with a total value of $117,050.00. Following the completion of the transaction, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 1,626,400 shares of company stock valued at $30,616,312. 0.65% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Viridian Therapeutics by 4.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after purchasing an additional 1,135 shares during the period. Swiss National Bank grew its position in shares of Viridian Therapeutics by 23.4% in the 1st quarter. Swiss National Bank now owns 82,900 shares of the company’s stock worth $1,452,000 after buying an additional 15,700 shares during the period. Vanguard Group Inc. increased its stake in shares of Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after acquiring an additional 233,331 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after acquiring an additional 799 shares during the period. Finally, American International Group Inc. boosted its stake in Viridian Therapeutics by 15.4% during the first quarter. American International Group Inc. now owns 24,515 shares of the company’s stock worth $429,000 after acquiring an additional 3,266 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.